272778-12-8

• 常用中文名：3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-(三甲基硅)氧]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-恶唑烷酮
• 常用英文名：3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(aMino)]][4-[triMethylsilyl]-oxy]phenyl]Methyl]-1-oxo-5-[(triMethylsily)-oxy]pentyl]-4-phenyl-(4S)-2-oxazolidinone
• CAS号：272778-12-8
• 分子式：C₃₉H₄₆F₂N₂O₅Si₂
• 分子量：716.961
• 相关类别： 原料药 循环系统用药 抗动脉粥样硬化药
• 发布时间：2018-11-24 07:01:57
• 更新时间：2026-07-02 10:30:16

名称

• 中文名: 3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-(三甲基硅)氧]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-恶唑烷酮
• 英文名: 3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][4-[trimethylsilyl]-oxy]phenyl]methyl]-1-oxo-5-[(trimethylsily)-oxy]pentyl]-4-phenyl-(4S)-2-oxazolidinone
• 中文别名: 氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-恶唑烷酮/272-8; 3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-(三甲基硅)氧]苯基]甲基]-1; 3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-(三甲基硅)氧]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-噁唑烷酮; 3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-(三甲基硅)氧]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]; 依替米贝中间体X; 依折麦布杂质9; (S)-3-((2R,5S)-5-(4-氟苯基)-2-((S)- (4-氟苯基氨基)(4-(三甲基硅氧基)苯基)甲基)-5-(三甲基硅氧基) 氧代戊基) -4-苯基-2-恶唑烷酮; S) -3-((2R,5S)-5-(4-氟苯基)-2-((S)-((4-氟苯)氨基)(4-(三甲基甲硅烷基)氧基)苯基)甲基)-5-((三甲基乙硅烷基)氧化基)戊酰基)-4-苯基恶唑烷-2-酮; 依折麦布I杂质; 依折麦布中间体; 依折麦布中间体一; (4S)-3-{(2R,5S)-5-(4- 氟苯基 )-2-[(S)-(4- 氟苯基 ) 氨基 ][4-( 三甲基硅氧基 ) 苯基 ] 甲基 }-1- 氧代 -(5- 三甲基硅氧基 ) 戊基 ]-4- 苯基 -2- 噁唑烷酮; 依折麦布杂质68; 依泽替米贝杂质9; (4S)-3-{(2R,5S)-5-(4-氟苯基 )-2-[(S)-(4-氟苯基 ) 氨基 ][4-( 三甲基硅氧基 ) 苯基 ] 甲基 }-1-氧代-(5-三甲基硅氧基 ) 戊基 ]-4-苯基-2-噁唑烷酮; (4S)-3-[(2R,5S)-5-(4-FLUOROPHENYL)-2-[(S)-[(4-FLUOROPHENYL)AMINO]-(4-TRIMETHYLSILYLOXYPHENYL)METHYL]-5-TRIMETHYLSILYLOXY-PENTANOYL]-4-PHENYL-1,3-OXAZOLIDIN-2-ONE3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基(氨基)]][4-(三甲基硅)氧]苯基]甲基]-1-氧代-5-[(三甲基硅)氧]苯基]-4-苯基-(4S)-2-恶唑烷酮; (4S)-3-[(2R,5S)-5-(4-氟苯基)-2-[(S)-[(4-氟苯基)氨基]({4-[(三甲基硅)氧]苯基})甲基]-5-[(三甲基硅)氧]正戊酰基]-4-苯基-1,3-恶唑烷-2-酮; (4S)-3-{(2R,5S)-5-(4-氟苯基)-2-[(S)-4(氟苯基)氨基][4-(三甲基硅氧基)苯基]甲基}-1-氧代-(5-三甲基硅氧基)戊基-4-苯基-2-恶唑烷酮; 依折麦布中间体ZT-6
• 英文别名: Ezetimibe Impuriry 9; (S)-3-((2R,5S)-5-(4-Fluorophenyl)-2-((S)-((4-fluorophenyl)aMino)(4-((triMethylsilyl)oxy)phenyl)Methyl)-5-((triMethylsilyl)oxy)pentanoyl)-4-phenyloxazolidin-2-one; Ezetimibe Impurity 68; 3-[(2r,5s)-5-(4-Fluorophenyl)-2-[(S)-[(4-Fluorophenyl( Amino)]][4-[Trimethylsilyl]-Oxy]Phenyl]Methyl]-1-Oxo-5-[(Trimethylsilyl)-Oxy]Pentyl]-4-Phenyl-(4s)-2-Oxazolidinone; Ezetimibe Impurity 9; Ezetimibe inter-X; Ezetimibe TMS intermediate; ZT-6; y)-oxy]pentyL; (4S)-3-{(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl)amino]{4-[(trimethylsilyl)oxy]phenyl}methyl]-5-[(trimethylsilyl)oxy]pentanoyl}-4-phenyl-1,3-oxazolidin-2-one; 2-OXAZOLIDINONE,3-[(2R,5S)-5-(4-FLUOROPHENYL)-2-[(S)-[(4-FLUOROPHENYL)AMINO][4-[(TRIMETHYLSILYL)OXY]PHENYL]METHYL]-1-OXO-5-[(TRIMETHYLSILYL)OXY]PENTYL]-4-PHENYL-,(4S); Ezetimibe Intermediate X; 3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][4-[trimethylsilyl]-oxy]phenyl]methyl]-1-oxo-5-[(trimethylsily)-oxy]pentyl]-4-phenyl-(4S; 3-[(2R,5S)-5-(4-FLUOROPHENYL)-2-[(S)-[(4-FLUOROPHENYL(AMINO)]] [4-[TRIMETHYLSILYL]-OXY]PHENYL]METHYL]-1-OXO-5-[(TRIMETHYLSILY)-OXY]PENTYL]-4-PHENYL-(4S)-2-OXAZOLIDINONE; 4S3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][4-[trimethylsilyl]- oxy]phenyl]methyl]-1-oxo-5-[(trimethylsily)-oxy]pentyl]-4-phenyl-(4S)-2-oxazolidinone; ]-1-oxo-5-[(trimethyL; (4S)-3-[(2R,5S)-5-(4-fluorophenyl)-2-[(S)-[(4-fluorophenyl)amino]-(4-trimethylsilyloxyphen yl)methyl]-5-trimethylsilyloxy-pentanoyl]-4-phenyl-1,3-oxazolidin-2-one; 3-[2-[(4-fluoroanilino)-(4-trimethylsilyloxyphenyl)methyl]-5-(4-fluorophenyl)-1-oxo-5-trimethylsilyloxypentyl]-4-phenyl-2-oxazolidinone; 3-((2R,5S)-5-(4-fluorophenyl)-2-(S)-((4-fluorophenyl)amino)(4-((trimethylsilyl)oxy)phenyl)methyl)-1-((trimethylsilyl)oxy)pentyl)-4-phenyl-(4S)-2-oxazolidinone; (4S)-2-oxazoL; E3:3-[(2R,5S)-5-(4-fluorophenyl)-2-{(S)-[(4-fluorophenyl)Amino]}[4-(trimethylsilyl)-oxy]pentyl]methyl-oxo-5-( trimethylsilyl)-oxo]penyl]-4-phenyl-(4S)-2-oxazolidinone; (amino)]][4-[trimethyL; 3-[(2R,5S)-5-(4- fluorophenyl) -2-[(S)-[(4- fluorophenyl (amino) ]][4- (trimethylsilyl) oxy] phenyl] methyl ]-1- oxo -5-[ (trimethylsilyl) oxy] phenyl; 3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][4-[trimethylsilyl]-oxy]phenyl]methyl]-1-oxo-5-[(trimethylsily)-oxy]pentyl]-4-phenyl-(4S)-2-oxazolidinone //BP; (4R)-3-[(2S,5R)-5-(4-Fluorophenyl)-2-[(R)-[(4-fluorophenyl)amino][4-[(trimethylsilyl)oxy]phenyl]methyl]-1-oxo-5-[(trimethylsilyl)oxy]pentyl]-4-phenyl-2-oxazolidinone; Ezetimibe Impurity 68 //BP; 3-[(2R,5S)-5-(4-FLUOROPHENYL)-2-[(S)-[(4-FLUOROPHENYL( AMINO)]] [4-[TRIMETHYLSILYL]-OXY]PHENYL]METHYL]-1-OXO-5-[(TRIMETHYLSILY)-OXY]PENTYL]-4-PHENYL-(4S)-2-OXAZOLIDINONE(INTERMEDIATE OF EZETIMIBE); 3-[(2R,5S)-5-(4-fluorophenyl)-2-{(S)-[4-fluorophenyl]Amino}[4-(trimethylsily)-oxy]pentyl]methyl-oxo-5-(trimethylsilyl)-oxo]penyl]-4-phenyl-(4S)-2-oxazolidinon; 3-[(2R,5S)-5-(4-fluorophenyl)-2-{(S)-[4-fluorophenyl]Amino}[4-(trimethylsily)-oxy]pentyl]methyl-1-2oxo-5-(trimethylsilyl)-oxo]penyl]-4-phenyl-(4S)-2-oxazolidinone; 3-(2R,5S)-5-(4-fluorophenyl)-2-(S)-(4-fluorophenyl(amino)4-trimethylsilyl-oxyphenylmethyl-1-oxo-5-(trimethylsily)-oxypentyl-4-phenyl-(4S)-2-oxazolidinone; 3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino); (4R)-3-[(2S,5R)-5-(4-Fluorophenyl)-2-[(R)-[(4-fluorophenyl)amino][4-[(trimethylsilyl)oxy]phenyl]meth; )-2-[(S)-[(4-fL; ]-oxy]phenyL; Ezetimibe INT 1; 3-[(2R,5S)-5-(4-FLUOROPHENYL)-2-[(S)-[(4-FLUOROPHENYL( AMINO)]] [4-[TRIMETHYLSILYL]-OXY]PHENYL]METHYL]-1-OXO-5-[(TRIMETHYLSILY) -OXY]PENTYL]-4-PHENYL-(4S)- 2-OXAZOLIDINONE(INTERMEDIATE OF EZETIMIBE); E3:3-[(2R,5S)-5-(4-fluorophenyl)-2-{(S)-[(4-fluorophenyl)Amino]}[4-(trimethylsilyl)-oxy]pentyl]methyl-1-2oxo-5-( trimethylsilyl)-oxo]penyl]-4-phenyl-(4S)-2-oxazolidinone; 3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][4-[trimethylsilyl]-oxy]phenyl]methyl]-1-oxo-5-[(trimethylsily)-oxy]pentyl]-4-phenyl-(4S)-2-oxazolidinone, min; 2-OXAZOLIDINONE, 3-[(2R,5S)-5-(4-FLUOROPHENYL)-2-[(S)-[(4-FLUOROPHENYL)AMINO][4-[(TRIMETHYLSILYL)OXY]PHENYL]METHYL]-1-OXO-5-[(TRIMETHYLSILYL)OXY]PENTYL]-4-PHENYL-, (4S); 3-[(2R,5S)-5-(4-fluorophenyl)-2-{(S)-[4-fluorophenyl]Amino}[4-(trimethylsily)-oxy]pentyl]methyl-oxo-5-(trimethylsilyl)-oxo]penyl]-4-phenyl-(4S)-2-oxazolidinone; {2-[3-(Fluorophenyl)-3-(trimethyl silyloxy)-propyl]-3-(4- fluoro phenyl amino) -3-(4-trimethyl silyloxy phenyl)-1- oxo-propyl}-4-(S) phenyl oxazolidin-2-one; 3-{(2R,5S)-5-(4-Fluoro-phenyl)-2-[(S)-(4-fluoro-phenylamino)-(4-trimethylsilanyloxy-phenyl)-methyl]-5-trimethylsilanyloxy-pentanoyl}-4(S)-phenyl-oxazolidin-2-one; 3-[(2R,5S)-5-(4-FL; 3- [(2R, 5S) -5- (4-fluorophenyl) -2- [(S) - [(4-fluorophenyl (amino) [4- (trimethylsiloxy) phenyl] methyl] -1-oxo-5- [(trimethylsiloxy) phenyl] -4-phenyl - (4S) -2-oxazolidinone; 3- [(2R, 5S) -5- (4-fluorophenyl) -2- [(S) - [(4-fluorophenyl (amino) [4- (trimethylsilyl) oxygen] phenyl] methyl] -1-oxo-5- [(trimethylsilyl) oxygen] phenyl] -4-phenyl - (4S) -2-oxazolidinone; (S)-3-((2R,5S)-5-(4-fluorophenyl)-2-((S)-((4-fluorophenyl)amino)(4-((trimethylsilyl)oxy)phenyl)methyl)-5-((trimethylsilyl)oxy)pentanoyl)-4-phenyloxazolidin-2-one (Intermediate of Ezetimibe); INTERMEDIATE OF EZETIMIBE

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 748.9±60.0 °C at 760 mmHg
• 分子式: C₃₉H₄₆F₂N₂O₅Si₂
• 分子量: 716.961
• 闪点: 406.7±32.9 °C
• 精确质量: 716.291321
• PSA: 77.10000
• LogP: 4.49
• 蒸汽压: 0.0±2.5 mmHg at 25°C
• 折射率: 1.566
• 储存条件: 2-8°C，避光，保存于惰性气体中

合成路线

75-77-4 189028-95-3 ~66% 272778-12-8

文献：US2006/135755 A1, ; Page/Page column 16-17 ;

75-77-4 10416-59-8 3382-63-6 189028-95-3 ~60% 详细

文献：WO2012/4382 A1, ; Page/Page column 25 ;

上下游产品

上游产品  4
75-77-4 189028-95-3 10416-59-8 3382-63-6
下游产品  0